Share
Market Research Report

GRAVES’ DISEASE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Segmentation
  • By Disease TypeOvert Graves’ Disease and Subclinical Graves’ Disease
  • By SymptomThyrotoxicosis · Graves Orbitopathy (Ocular) · Dermopathy (Pretibial Myxedema) · and Other Systemic Manifestations
  • By Diagnostic MethodClinical Evaluation · Imaging (Ultrasound, Radioiodine Uptake Scan, MRI/CT (for orbitopathy)) · and Laboratory (TSH, Free T3/Free T4, TSH Receptor Antibodies (TRAb))
  • By Treatment ModalityPharmacological (Antithyroid Drugs (Methimazole, Propylthiouracil, and Carbimazole), Beta‑Blockers, Corticosteroids, Immunosuppressants) · Radioactive Iodine Therapy · Surgical (Total Thyroidectomy and Subtotal Thyroidectomy) · Adjunctive/Ocular(Orbital Decompression, Rituximab, and Teprotumumab) · and Supportive/Other (Lifestyle/Adjunctive Care)
  • By End UserHospitals · Specialty Clinics · Diagnostic Centers · Ambulatory Surgical Centers · and Home Care Settings
  • By Distribution ChannelHospital Pharmacies · Retail Pharmacies · and Online Pharmacies
  • By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
  • Published In16 Feb 2026
  • Report CodeCMI9337
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026 - 2033

Market Segmentation

  • Disease Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Overt Graves’ Disease
    • Subclinical Graves’ Disease

  • Symptom Insights (Revenue, USD Bn, 2021 - 2033)

    • Thyrotoxicosis
    • Graves Orbitopathy (Ocular)
    • Dermopathy (Pretibial Myxedema)
    • Other Systemic Manifestations

  • Diagnostic Method Insights (Revenue, USD Bn, 2021 - 2033)

    • Clinical Evaluation
    • Imaging
      • Ultrasound
      • Radioiodine Uptake Scan
      • MRI/CT (for orbitopathy)
    • Laboratory
      • TSH
      • Free T3/Free T4
      • TSH Receptor Antibodies (TRAb)

  • Treatment Modality Insights (Revenue, USD Bn, 2021 - 2033)

    • Pharmacological
      • Antithyroid Drugs
        • Methimazole
        • Propylthiouracil
        • Carbimazole
      • Beta Blockers
      • Corticosteroids
      • Immunosuppressants
    • Radioactive Iodine Therapy
    • Surgical
      • Total Thyroidectomy
      • Subtotal Thyroidectomy
    • Adjunctive/Ocular
      • Orbital Decompression
      • Rituximab
      • Teprotumumab
    • Supportive/Other
      • Lifestyle/Adjunctive Care

  • End User Insights (Revenue, USD Bn, 2021 - 2033)

    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • Ambulatory Surgical Centers
    • Home Care Settings

  • Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

  • Regional Insights (Revenue, USD Bn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa